Managing Partner & CIO
Roderick Wong, MD, serves as Managing Partner and Chief Investment Officer of RTW Investments, LP (“RTW”). Dr. Wong is responsible for managing the firm’s investments focused on innovative scientific assets and companies specialized in disruptive and curative drug development. Prior to forming RTW, Dr. Wong was a Managing Director and sole Portfolio Manager for the Davidson Kempner Healthcare Funds. Before joining Davidson Kempner, Dr. Wong held various healthcare investment and research roles at Sigma Capital Partners and Cowen & Company.
Dr. Wong regularly serves on corporate boards, including serving as Chairman of the Board of Rocket Pharmaceuticals (“Rocket”), since Rocket’s inception in July 2015, a publicly traded gene therapy company. He also serves on the board of directors of Attune Pharmaceuticals, a privately held biotechnology company.
Dr. Wong simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.
Dr. Wong has a keen interest in educating the next generation of life science entrepreneurs. He regularly sits on a variety of corporate boards. In addition, he serves on the board of Penn Medicine, as an Adjunct Associate Professor of Finance at NYU Stern, and as Chairman of the RTW Charitable Foundation.